(Date:5/16/2008)...l HIV Vaccine Awareness Day, May,18, WASHINGTON, ... into the,AIDS epidemic, someone is newly infected...May 18, HIV Vaccine Awareness Day, AIDS Action, on...ute of Allergy and Infectious,Disease (NIAID) HIV ...one,to help end the AIDS epidemic by participating...
(Date:5/16/2008)... most from chemo after surgery, study says , ...of 15 genes may help determine which patients with...ience a recurrence and, therefore, benefit the mos...xtension, the same genetic signature may also iden...ncer who would be able to forego chemotherapy. ,...
(Date:5/16/2008)...th plc (LSE: HNT), "the Group",a leading internat...ns,group headquartered in London, released its int... performance in the first quarter 2008 (the period... below., 15 May 2008, ...nagement Statement, Record net new bus...
(Date:5/16/2008)...arn the lesson of helping others i...ina, May 16 /PRNewswire/ -- In the aftermath of th...t members of China are,looking for ways to join in...ountry, schools are running donation drives and fu...l, Ms. Zhang Lijun, the 190-student strong,Nanjing...
Breaking Medicine News(10 mins):Health News:AIDS Action Urges Everyone to Help End the AIDS Epidemic by Being Part of the Search for an HIV Vaccine 2Health News:Gene Signature May Predict Recurrence of Lung Cancer 2Health News:Gene Signature May Predict Recurrence of Lung Cancer 3Health News:Huntsworth plc Releases Interim Statement on First Quarter 2008 2Health News:Huntsworth plc Releases Interim Statement on First Quarter 2008 3Health News:Huntsworth plc Releases Interim Statement on First Quarter 2008 4Health News:Chinese Preschoolers Participate in Fund Drive to Help the Victims of Sichuan Quake 2...'s B.M. Birla Heart Research Centre Friday became ...ccreditation// in recognition of its high quality ...r Hospitals and Health Service Providers (NABH) ce...nt of our focus on quality", Suyash Borar, the hos...
...e of the biggest controversies in fetal surgery an...ternal-fetal medicine physicians// around the worl...ion syndrome (TTTS), one of the most common condit...eading cause of mortality in twins? The benchmark...
...ne Sherwood-Puzzello, a clinical assistant profess...of Applied Health Science//, has offered some tips...on sex with their teenage children. Teenage is th...of growing up. Love and romance form an integral p...
...rch aimed to study the significance of thyroid che...searchers are considering whether thyroid check up...if no symptoms of the disease are seen. Previous s...y under active or a hyperactive thyroid gland duri...
Other Medicine News:Health News:Timeliness, a Critical Factor in Treating TTTS 2Health News:Timeliness, a Critical Factor in Treating TTTS 3Health News:Pregnant? Check Your Thyroid Secretion! 2(Date:5/16/2008)... Highlights Include:, -- Results demonstrating ... clinically meaningful extension of progression-fr...zumab to attack both the inside and,outside of the...ckade, -- Data demonstrating activity of TYKERB a...tiple lines of trastuzumab and chemotherapy, LOND...
(Date:5/16/2008)... - ANX-530 Demonstrates Statistically Significant ...fety Observations, - Abstract to be published in 2... Clinical Oncology, SAN DIEGO, ...uticals,Inc. (Amex: ANX ) announced today that, ... ANX-530 demonstrated a statistically significant ...
(Date:5/15/2008)... - First in human clinical data highlight safety ...h advanced solid tumors -, BRISBANE, Calif., May ...ly held biopharmaceutical company developing novel...rting its lead PARP inhibitor, BSI-201, will,be pr...ncology annual,meeting in Chicago., Findings will...
(Date:5/15/2008)... KENILWORTH, N.J., May 15 /PRNewswire-FirstCall/...eader in advancing the science and treatment of,ch... today that data from,several clinical studies wit...L(R) (ribavirin, USP) combination therapy, as well... HCV protease inhibitor, will be presented at,the ...
Breaking Medicine Technology:GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 2GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 3GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 4GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 5GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 6GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 7ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 2ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 3ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 4ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 5BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting 2Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 2Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 3Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 4Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 5Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 6Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 7Family history of alcoholism affects response to drug used to treat heavy drinking 1563 1Family history of alcoholism affects response to drug used to treat heavy drinking 1563 2New study shows fish respond quickly to changes in mercury deposition 452 1New study shows fish respond quickly to changes in mercury deposition 452 2New study shows fish respond quickly to changes in mercury deposition 452 3 3Ci 3ECosby 3C i 3E Star Tackles a Silent Heart Threat 1557 1 3Ci 3ECosby 3C i 3E Star Tackles a Silent Heart Threat 1557 2 3Ci 3ECosby 3C i 3E Star Tackles a Silent Heart Threat 1557 3 3Ci 3ECosby 3C i 3E Star Tackles a Silent Heart Threat 1557 4IsoTis Integra Merger 678 1IsoTis Integra Merger 678 2IsoTis Integra Merger 678 3IsoTis Integra Merger 678 4IsoTis Integra Merger 678 5...RN, Pa.--(BUSINESS WIRE)--Mar 7, 2007 - Gemin X,an...e version of,the journal Blood demonstrated that i...tent cytotoxic responses against,patient-derived m...,enhanced anti-myeloma effects when used as a comb...ifically designed to inhibit all,relevant members ...
...NESS WIRE)--Mar 7, 2007 - Advanced Viral,Research ...cal,company, announced today that new information ... 2007 Proceedings of the American,Society of Clini...lication will be distributed to the nearly 25,000 ...ar,s meeting in Chicago on,June 1-5., Based on rec...
Other Medicine Technology:Gemin X Announces Publication of Preclinical Data of GX15-070 in,Multiple Myeloma in Blood 2American Society of Clinical Oncology (ASCO) Accepts New Data on,AVR118 for Publication in 2007 Abstract Book 2American Society of Clinical Oncology (ASCO) Accepts New Data on,AVR118 for Publication in 2007 Abstract Book 3The Vitek 2 is a fully automated bacteriology system that performs bacterial identification and susceptibility testing analysis using a standard inoculum. It detects resistance and helps combat bacte
IDS Rapid ANA II System, a microbial identification system.
IDS Rapid SS/u, a microbial identification system.
IDS Rapid NF Plus, a microbial identification system.
Medicine Products: